Tenderwize
Back to tender search

Open-house drug rebate agreements Brandenburg

AOK Nordost - Die Gesundheitskasse·Potsdam, Germany·Deadline Feb 21, 2027 · 138 days left·Open·Supplies
Structured notice only
Original notice title

Germany – Pharmaceutical products – Open-House-Arzneimittelrabattverträge gemäß § 130a Abs. 8c SGB V für die KV-Region Brandenburg

57/100

Opportunity Score

Needs reviewMedium complexity
SuppliesOpen
Why this score?

Opportunity

57 / 100

Complexity

61 / 100

Risk factors

The lot descriptions state a latest contract-conclusion date of 21 February 2026, whereas the structured/XML deadline i...

No estimated value, quantities, expected demand or guaranteed volume is disclosed in the provided data, so potential re...

Deep Portfolio Analysis

Deep Company Fit Analysis

Uses:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Tender facts

Contracting authority
AOK Nordost - Die Gesundheitskasse
Country
Germany
CPV
33600000 - Pharmaceutical products
Deadline
Feb 21, 2027

Overview

Moderate opportunity

Key Facts

  • Supplies contract
  • 3 lots
  • Duration until Apr 2027
  • Conclusion of non-exclusive drug discount agreements under Section 130a(8c) SGB V for the Brandenburg statutory health-insurance region.
  • Supply-related scope covering pharmacy-prepared parenteral oncology preparations made from finished medicinal products for immediate physician administration to patients.
Show full summary

Open-house pharmaceutical discount agreements under Section 130a(8c) SGB V for the Brandenburg statutory health-insurance region, covering Bevacizumab, Rituximab and Trastuzumab. The buyer states that every interested pharmaceutical company meeting the published requirements may join on identical, non-negotiable terms and that no supplier selection is made. Contracts are planned from 1 May 2026 to 30 April 2027, subject to earlier termination or automatic suspension if a relevant nationwide or regional discount agreement enters into force. Procurement documents are referenced through the DTVP portal but were not provided for analysis. The structured final deadline is 21 February 2027, while the lot descriptions state that contract conclusion is possible only until 21 February 2026; this material inconsistency must be clarified.

Risks

The lot descriptions state a latest contract-conclusion date of 21 February 2026, whereas the structured/XML deadline i...

No estimated value, quantities, expected demand or guaranteed volume is disclosed in the provided data, so potential re...

Analysis may be incomplete

Only part of the procurement documentation was analyzed. Additional eligibility requirements, certificates, or submission documents may exist in the remaining tender documentation.

Key Requirements

Technical

  • Only pharmaceutical companies may participate as potential contract partners.
  • The contract terms are pre-established, identical and not individually negotiable.

Administrative

  • The completed and signed agreement must be submitted together with the completed PZN file named OHV_8c_Brandenburg_Festlegung_[Wirkstoffname]_PZN.

Requirements may be incomplete.

Buyer

Location

Potsdam, DEU

Website

www.aok.de

Identifier

DE275390265

Activity

Health

Lots (3)

LOT-0001

Bevacizumab

Open-house, non-exclusive pharmaceutical discount agreement for Bevacizumab (ATC L01FG01), concerning pharmacy-prepared parenteral oncology preparations from finished medicinal products for immediate physician administration to patients in the Brandenburg region. The agreement is offered to all eligible interested pharmaceutical companies on identical non-negotiable terms.

SuppliesEU fundedElectronic submission

Location

Germany

Duration

Apr 2026 - Apr 2027

Category

Pharmaceutical products

Deadline

Deadline Feb 21, 2027

LOT-0002

Rituximab

Open-house, non-exclusive pharmaceutical discount agreement for Rituximab (ATC L01FA01), concerning pharmacy-prepared parenteral oncology preparations from finished medicinal products for immediate physician administration to patients in the Brandenburg region. The agreement is offered to all eligible interested pharmaceutical companies on identical non-negotiable terms.

SuppliesEU fundedElectronic submission

Location

Germany

Duration

Apr 2026 - Apr 2027

Category

Pharmaceutical products

Deadline

Deadline Feb 21, 2027

LOT-0003

Trastuzumab

Open-house, non-exclusive pharmaceutical discount agreement for Trastuzumab (ATC L01FD01), concerning pharmacy-prepared parenteral oncology preparations from finished medicinal products for immediate physician administration to patients in the Brandenburg region. The agreement is offered to all eligible interested pharmaceutical companies on identical non-negotiable terms.

SuppliesEU fundedElectronic submission

Location

Germany

Duration

Apr 2026 - Apr 2027

Category

Pharmaceutical products

Deadline

Deadline Feb 21, 2027

Procurement Details

Publication date
11 Feb 2026
Languages
German

Reference metadata

Legal basis
32014L0024

Reference IDs

Tender ID
100552-2026

Documents (2)

Similar tenders